Recent Finacing
Recent Raise
Anelixis Therapeutics develops engineered humanized anti‑CD40L antibodies, advancing lead AT-1501—completed Phase 1 safety/PK, optimized cGMP manufacturing, and activity in preclinical models for ALS, transplant rejection, autoimmune disease.
